First Line Ipilimumab+Nivolumab Combined with two cycles of Chemotherapy in NSCLC [FINN]

CAPTOR‐BC ‐ Umfassende Analyse der räumlichen, zeitlichen und molekularen Muster bezüglich der Wirksamkeit und Resistenz von Ribociclib bei Patientinnen mit fortgeschrittenem Brustkrebs

Chirurgische Therapie für das Adenokarzinom des gastroösophagealen Überganges (AEG Typ II): Transthorakale Ösophagektomie vs. Transhiatal erweiterte Gastrektomie.

An open-Label, multi-Center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued Treatment with ceritinib

Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focos on digital side effect management

Retentionsrate von Acalabrutinib in einem nicht-interventionellen Setting